<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39580703</PMID><DateRevised><Year>2024</Year><Month>11</Month><Day>24</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1326-5377</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2024</Year><Month>Nov</Month><Day>24</Day></PubDate></JournalIssue><Title>The Medical journal of Australia</Title><ISOAbbreviation>Med J Aust</ISOAbbreviation></Journal><ArticleTitle>Towards a cure for long COVID: the strengthening case for persistently replicating SARS-CoV-2 as a driver of post-acute sequelae of COVID-19.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.5694/mja2.52517</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Scoullar</LastName><ForeName>Michelle Jl</ForeName><Initials>MJ</Initials><Identifier Source="ORCID">0000-0003-1417-1524</Identifier><AffiliationInfo><Affiliation>Burnet Institute, Melbourne, VIC.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinic Nineteen, Melbourne, VIC.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Khoury</LastName><ForeName>Gabriela</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Burnet Institute, Melbourne, VIC.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Monash University, Melbourne, VIC.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Majumdar</LastName><ForeName>Suman S</ForeName><Initials>SS</Initials><Identifier Source="ORCID">0000-0002-9656-557X</Identifier><AffiliationInfo><Affiliation>Burnet Institute, Melbourne, VIC.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Monash University, Melbourne, VIC.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tippett</LastName><ForeName>Emma</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0001-9038-6952</Identifier><AffiliationInfo><Affiliation>Burnet Institute, Melbourne, VIC.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinic Nineteen, Melbourne, VIC.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Crabb</LastName><ForeName>Brendan S</ForeName><Initials>BS</Initials><AffiliationInfo><Affiliation>Burnet Institute, Melbourne, VIC.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Monash University, Melbourne, VIC.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University of Melbourne, Melbourne, VIC.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>11</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>Australia</Country><MedlineTA>Med J Aust</MedlineTA><NlmUniqueID>0400714</NlmUniqueID><ISSNLinking>0025-729X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID&#x2010;19</Keyword><Keyword MajorTopicYN="N">Chronic fatigue syndrome</Keyword><Keyword MajorTopicYN="N">SARS&#x2010;CoV&#x2010;2</Keyword><Keyword MajorTopicYN="N">Virus diseases</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>6</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>10</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>11</Month><Day>25</Day><Hour>1</Hour><Minute>10</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>11</Month><Day>25</Day><Hour>1</Hour><Minute>10</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>11</Month><Day>24</Day><Hour>9</Hour><Minute>2</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39580703</ArticleId><ArticleId IdType="doi">10.5694/mja2.52517</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Davis HE, McCorkell L, Vogel JM, Topol EJ. Long COVID: major findings, mechanisms and recommendations. Nat Rev Microbiol 2023; 21: 133&#x2010;146.</Citation></Reference><Reference><Citation>Merad M, Blish CA, Sallusto F, Iwasaki A. The immunology and immunopathology of COVID&#x2010;19. Science 2022; 375: 1122&#x2010;1127.</Citation></Reference><Reference><Citation>Office for National Statistics. Self&#x2010;reported coronavirus (COVID&#x2010;19) infections and associated symptoms, England and Scotland: November 2023 to March 2024 [website]. ONS, 2024. https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/articles/selfreportedcoronaviruscovid19infectionsandassociatedsymptomsenglandandscotland/november2023tomarch2024 (viewed Apr 2024).</Citation></Reference><Reference><Citation>National Center for Health Statistics. US Census Bureau, Household Pulse Survey, 2022&#x2013;2024. Long COVID. Generated interactively [website]. CDC, 2024. https://www.cdc.gov/nchs/covid19/pulse/long&#x2010;covid.htm (viewed May 2024).</Citation></Reference><Reference><Citation>Bowe B, Xie Y, Al&#x2010;Aly Z. Postacute sequelae of COVID&#x2010;19 at 2 years. Nat Med 2023; 29: 2347&#x2010;2357.</Citation></Reference><Reference><Citation>Woldegiorgis M, Cadby G, Ngeh S, et&#xa0;al. Long COVID in a highly vaccinated but largely unexposed Australian population following the 2022 SARS&#x2010;CoV&#x2010;2 Omicron wave: a cross&#x2010;sectional survey. Med J Aust 2024; 220: 323&#x2010;330. https://www.mja.com.au/journal/2024/220/6/long&#x2010;covid&#x2010;highly&#x2010;vaccinated&#x2010;largely&#x2010;unexposed&#x2010;australian&#x2010;population&#x2010;following</Citation></Reference><Reference><Citation>Ledford H. Long COVID is a double curse in low&#x2010;income nations &#x2014; here's why [media release]. Nature, 2024. https://www.nature.com/articles/d41586&#x2010;023&#x2010;04088&#x2010;x (viewed May 2024).</Citation></Reference><Reference><Citation>Rao S, Gross RS, Mohandas S, et&#xa0;al. Postacute sequelae of SARS&#x2010;CoV&#x2010;2 in children. Pediatrics 2024; 153: e2023062570.</Citation></Reference><Reference><Citation>Appelman B, Charlton BT, Goulding RP, et&#xa0;al. Muscle abnormalities worsen after post&#x2010;exertional malaise in long COVID. Nat Commun 2024; 15: 17.</Citation></Reference><Reference><Citation>Fedorowski A, Fanciulli A, Raj SR, et&#xa0;al. Cardiovascular autonomic dysfunction in post&#x2010;COVID&#x2010;19 syndrome: a major health&#x2010;care burden. Nat Rev Cardiol 2024; 21: 379&#x2010;395.</Citation></Reference><Reference><Citation>Greene C, Connolly R, Brennan D, et&#xa0;al. Blood&#x2013;brain barrier disruption and sustained systemic inflammation in individuals with long COVID&#x2010;associated cognitive impairment. Nat Neurosci 2024; 27: 421&#x2010;432.</Citation></Reference><Reference><Citation>Hampshire A, Azor A, Atchison C, et&#xa0;al. Cognition and memory after Covid&#x2010;19 in a large community sample. N Engl J Med 2024; 390: 806&#x2010;818.</Citation></Reference><Reference><Citation>Cervia&#x2010;Hasler C, Br&#xfc;ningk SC, Hoch T, et&#xa0;al. Persistent complement dysregulation with signs of thromboinflammation in active Long Covid. Science 2024; 383: eadg7942.</Citation></Reference><Reference><Citation>Davitt E, Davitt C, Mazer MB, et&#xa0;al. COVID&#x2010;19 disease and immune dysregulation. Best Pract Res Clin Haematol 2022; 35: 101401.</Citation></Reference><Reference><Citation>Yin K, Peluso MJ, Luo X, et&#xa0;al. Long COVID manifests with T cell dysregulation, inflammation and an uncoordinated adaptive immune response to SARS&#x2010;CoV&#x2010;2. Nat Immunol 2024; 25: 218&#x2010;225.</Citation></Reference><Reference><Citation>Phetsouphanh C, Darley DR, Wilson DB, et&#xa0;al. Immunological dysfunction persists for 8 months following initial mild&#x2010;to&#x2010;moderate SARS&#x2010;CoV&#x2010;2 infection. Nat Immunol 2022; 23: 210&#x2010;216.</Citation></Reference><Reference><Citation>Phetsouphanh C, Jacka B, Ballouz S, et&#xa0;al. Improvement of immune dysregulation in individuals with long COVID at 24&#x2010;months following SARS&#x2010;CoV&#x2010;2 infection. Nat Commun 2024; 15: 3315.</Citation></Reference><Reference><Citation>Chen B, Julg B, Mohandas S, Bradfute SB, RECOVER Mechanistic Pathways Task Force. Viral persistence, reactivation, and mechanisms of long COVID. eLife 2023; 12: e86015.</Citation></Reference><Reference><Citation>Proal AD, VanElzakker MB, Aleman S, et&#xa0;al. SARS&#x2010;CoV&#x2010;2 reservoir in post&#x2010;acute sequelae of COVID&#x2010;19 (PASC). Nat Immunol 2023; 24: 1616&#x2010;1627.</Citation></Reference><Reference><Citation>Ghafari M, Hall M, Golubchik T, et&#xa0;al. Prevalence of persistent SARS&#x2010;CoV&#x2010;2 in a large community surveillance study. Nature 2024; 626: 1094&#x2010;1101.</Citation></Reference><Reference><Citation>Menezes SM, Jamoulle M, Carletto MP, et&#xa0;al. Blood transcriptomic analyses reveal persistent SARS&#x2010;CoV&#x2010;2 RNA and candidate biomarkers in post&#x2010;COVID&#x2010;19 condition. Lancet Microbe 2024; 5: 100849.</Citation></Reference><Reference><Citation>Peluso MJ, Swank ZN, Goldberg SA, et&#xa0;al. Plasma&#x2010;based antigen persistence in the post&#x2010;acute phase of COVID&#x2010;19. Lancet Infect Dis 2024; 24: E345&#x2010;E347.</Citation></Reference><Reference><Citation>Zuo W, He D, Liang C, et&#xa0;al. The persistence of SARS&#x2010;CoV&#x2010;2 in tissues and its association with long COVID symptoms: a cross&#x2010;sectional cohort study in China. Lancet Infect Dis 2024; 24: 845&#x2010;855.</Citation></Reference><Reference><Citation>Zollner A, Koch R, Jukic A, et&#xa0;al. Postacute COVID&#x2010;19 is characterized by gut viral antigen persistence in inflammatory bowel diseases. Gastroenterology 2022; 163: 495&#x2010;506.</Citation></Reference><Reference><Citation>Platt A, Singh M, Stein S, et&#xa0;al. Replication&#x2010;competent virus detected in blood of a fatal COVID&#x2010;19 case. Ann Intern Med 2024; 177: 113&#x2010;135.</Citation></Reference><Reference><Citation>Xu E, Xie Y, Al&#x2010;Aly Z. Long&#x2010;term gastrointestinal outcomes of COVID&#x2010;19. Nat Commun 2023; 14: 983.</Citation></Reference><Reference><Citation>Zhu A, Real F, Capron C, et&#xa0;al. Infection of lung megakaryocytes and platelets by SARS&#x2010;CoV&#x2010;2 anticipate fatal COVID&#x2010;19. Cell Mol Life Sci 2022; 79: 365.</Citation></Reference><Reference><Citation>Catal&#xe0; M, Mercad&#xe9;&#x2010;Besora N, Kolde R, et&#xa0;al. The effectiveness of COVID&#x2010;19 vaccines to prevent long COVID symptoms: staggered cohort study of data from the UK, Spain, and Estonia. Lancet Respir Med 2024; 12: 225&#x2010;236.</Citation></Reference><Reference><Citation>Xie Y, Choi T, Al&#x2010;Aly Z. Postacute sequelae of SARS&#x2010;CoV&#x2010;2 infection in the pre&#x2010;Delta, Delta, and Omicron eras. N Engl J Med 2024; 391: 515&#x2010;525.</Citation></Reference><Reference><Citation>Bramante CT, Beckman KB, Mehta T, et&#xa0;al. Favorable antiviral effect of metformin on severe acute respiratory syndrome Coronavirus 2 viral load in a randomized, placebo&#x2010;controlled clinical trial of Coronavirus disease 2019. Clin Infect Dis 2024; 79: 354&#x2010;363.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>